

## PRIOR AUTHORIZATION POLICY

**POLICY:** Inflammatory Conditions – Siliq Prior Authorization Policy

- Siliq® (brodalumab subcutaneous injection – Valeant Pharmaceuticals)

**REVIEW DATE:** 05/04/2022

---

### OVERVIEW

Siliq, an interleukin (IL)-17A antagonist, is indicated for treatment of adults with moderate to severe **plaque psoriasis** who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.<sup>1</sup> In the pivotal trial, patients were assessed for a response at Week 12.

### Guidelines

Joint guidelines from the American Academy of Dermatology and National Psoriasis Medical Board (2019) have been published for management of psoriasis with biologics.<sup>2</sup> These guidelines list Siliq as a monotherapy treatment option for patients with moderate to severe plaque psoriasis. Guidelines from the European Dermatology Forum (2015) recommend biologics (i.e., etanercept, adalimumab, infliximab, Stelara® [ustekinumab subcutaneous injection]) as second-line therapy for induction and long-term treatment if phototherapy and conventional systemic agents have failed, are contraindicated, or are not tolerated.<sup>3</sup>

### Safety

Siliq has a Boxed Warning, Risk Evaluation and Mitigation Strategy (REMS) program, and limited distribution program due to risks of suicidal ideation and behavior. The REMS program requires prescribers and pharmacies to be certified to prescribe and/or dispense Siliq.<sup>4</sup> Patients must sign a patient-prescriber agreement form and be aware of the need to seek medical attention for any new/worsening suicidal thoughts or behavior, depression, anxiety, or mood changes.

### POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of Siliq. Because of the specialized skills required for evaluation and diagnosis of patients treated with Siliq as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Siliq to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days.

**Automation:** None.

### RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Siliq is recommended in those who meet the following criteria:

## FDA-Approved Indication

1. **Plaque Psoriasis.** Approve for the duration noted if the patient meets ONE of the following (A or B):
  - A) **Initial Therapy.** Approve for 3 months if the patient meets ALL of the following criteria (i, ii, and iii):
    - i. Patient is  $\geq 18$  years of age; AND
    - ii. Patient meets ONE of the following conditions (a or b):
      - a) Patient has tried at least at least one traditional systemic agent for psoriasis for at least 3 months, unless intolerant; OR  
Note: Examples include methotrexate, cyclosporine, acitretin, or psoralen plus ultraviolet A light (PUVA). An exception to the requirement for a trial of one traditional systemic agent for psoriasis can be made if the patient has already had a 3-month trial or previous intolerance to at least one biologic other than the requested drug. A biosimilar of the requested biologic does not count. Refer to [Appendix](#) for examples of biologics used for plaque psoriasis. A patient who has already tried a biologic for psoriasis is not required to “step back” and try a traditional systemic agent for psoriasis.
      - b) Patient has a contraindication to methotrexate, as determined by the prescriber; AND
    - iii. The medication is prescribed by or in consultation with a dermatologist.
  - B) **Patient is Currently Receiving Siliq.** Approve for 1 year if the patient meets ALL of the following (i, ii, and iii):
    - i. Patient has been established on therapy for at least 90 days; AND  
Note: A patient who has received < 90 days of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
    - ii. Patient experienced a beneficial clinical response, defined as improvement from baseline (prior to initiating Siliq) in at least one of the following: estimated body surface area, erythema, induration/thickness, and/or scale of areas affected by psoriasis; AND
    - iii. Compared with baseline (prior to receiving Siliq), patient experienced an improvement in at least one symptom, such as decreased pain, itching, and/or burning.

## CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Siliq is not recommended in the following situations:

1. **Concurrent Use with other Biologics or with Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs).** Siliq should not be administered in combination with a biologic used for an inflammatory condition (see [Appendix](#) for examples). Combination therapy with biologics and/or biologics + targeted synthetic DMARDs has a potential for a higher rate of adverse effects and lack controlled trial data in support of additive efficacy.  
Note: This does NOT exclude the use of conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine) in combination with Siliq.
2. **Crohn’s Disease.** Siliq is contraindicated in patients with Crohn’s disease.<sup>1</sup> There is a published Phase II study evaluating Siliq in Crohn’s disease (n = 130) that was terminated early due to a disproportionate number of worsening Crohn’s disease and lack of efficacy.<sup>5</sup>
3. **Rheumatoid Arthritis.** Efficacy has not been established. A published Phase II study (n = 252) did not demonstrate improvement in American College of Rheumatology 20/50/70 responses with Siliq vs. placebo for treatment of rheumatoid arthritis in patients who had previously failed methotrexate.<sup>6</sup>

- Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

**REFERENCES**

- Siliq<sup>®</sup> subcutaneous injection [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; February 2017.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol.* 2019 80(4):1029-1072.
- Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and IPC. *J Eur Acad Dermatol Venereol.* 2015;29(12):2277-2294.
- US Food and Drug Administration, US Department of Health and Human Services [Web site]. <https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvReMSDetails.page&REMS=362>. Search term: Siliq. Updated January 22, 2021. Accessed on May 2, 2022.
- Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled Phase 2 study of brodalumab in patients with moderate-to-severe Crohn's disease. *Am J Gastroenterol.* 2016;111(11):1599-1607.
- Pavelka K, Chon Y, Newmark R, et al. A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate. *J Rheumatol.* 2015;42(6):912-919.

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	04/21/2021
Selected Revision	<b>Plaque Psoriasis:</b> Note was clarified to state that a previous trial of a biologic applies to one biologic other than the requested drug. For a patient currently receiving, it was clarified that this applies to a patient who has received for ≥ 90 days. Requirements were added for a patient who is currently receiving, that there is has at least one objective and at least one subjective response to therapy. For continuation, approvals were changed to be 1 year in duration. Previously, response was more general and according to the prescriber, and approvals were for 3 years.	12/01/2021
Annual Revision	No criteria changes.	05/04/2022

**APPENDIX**

\* Not an all-inclusive list of indications (e.g., oncology indications and rare inflammatory conditions are not listed). Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; ^ Off-label use of Kineret in JIA supported in guidelines; ERA – Enthesitis-related arthritis; DMARD – Disease-modifying antirheumatic drug; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis.